A significant clinical advance has emerged for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Data presented at the European Hematology Association’s 2026 annual congress in Stockholm reveal that adding pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to the established venetoclax-rituximab combination therapy substantially improves progression-free survival.
This triple-drug approach represents a meaningful clinical benefit for heavily pretreated patients who have exhausted standard treatment options. Rather than replacing existing combination therapy, pirtobrutinib enhances the regimen by targeting resistance mechanisms that emerge with earlier-generation BTK inhibitors. The finding opens new therapeutic pathways for this challenging patient population facing limited alternatives.
Read the full article on GMJ Newsroom.
Was this article helpful?
